StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TRDABullishResearch Analysisnews
Materiality pending

Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?

Jul 25, 2024, 11:02 AM EDT1 sourcesAI-analyzed

AI summary

What happened, with direct paths to the underlying reporting

TRDA closed at $16.17, gaining 14.7% in four weeks. Mean price target of $20.33 indicates 25.7% upside potential. Strong analyst agreement in earnings estimate revisions suggests positive outlook. TRDA has a Zacks Rank #1 (Strong Buy), indicating strong potential upside. Analysts caution against solely relying on price targets for investing.

  • TRDA closed at $16.17, gaining 14.7% in four weeks.
  • Mean price target of $20.33 indicates 25.7% upside potential.
  • Strong analyst agreement in earnings estimate revisions suggests positive outlook.
  • TRDA has a Zacks Rank #1 (Strong Buy), indicating strong potential upside.
  • Analysts caution against solely relying on price targets for investing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.